<DOC>
	<DOC>NCT01563978</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.</brief_summary>
	<brief_title>Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Male and female patients aged 18 or over diagnosed with rheumatoid arthritis after the age of 16 Active rheumatoid arthritis defined as: ≥4 swollen joints and ≥4 tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate ≥28 mm/h, or Creactive protein ≥10 mg/L. Currently taking one of the following diseasemodifying antirheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine. Patients without essential hypertension or with essential hypertension if their blood pressure is controlled (&lt;140/90 mmHg) with antihypertensive medications being stable at least 4 weeks prior to randomisation. Females who are pregnant or breastfeeding. Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders History of liver problems that have required previous investigations Evidence of tuberculosis infection Conditions that preclude or render difficult the 24hour ambulatory blood pressure monitoring technique.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>